Annals of Emergency Medicine
Volume 54, Issue 2 , Pages 181-190 , August 2009

Ketamine and Neurotoxicity: Clinical Perspectives and Implications for Emergency Medicine

  • Steven M. Green, MD

      Affiliations

    • Department of Emergency Medicine, Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA
    • Corresponding Author InformationAddress for correspondence: Steven Green, MD, Loma Linda University Medical Center A-108, 11234 Anderson Street, Loma Linda, CA 92354; 805-969-2144, Fax 775-307-4121
    • ,
  • Charles J. Coté, MD

      Affiliations

    • Department of Anesthesia and Critical Care, Harvard Medical School and MassGeneral Hospital for Children at Massachusetts General Hospital, Boston, MA

Received 9 September 2008 ,Revised 23 September 2008 ,Accepted 1 October 2008.

References 

  1. Bhargava R, Young KD. Procedural pain management patterns in academic pediatric emergency departments. Acad Emerg Med. 2007;14:479–482
  2. Haley-Andrews S. Ketamine: the sedative of choice in a busy pediatric emergency department. J Emerg Nurs. 2006;32:186–188
  3. Green SM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation in children. Ann Emerg Med. 2004;44:460–471
  4. Mace SE, Barata IA, Cravero JP, et al. Clinical policy: evidence-based approach to pharmacologic agents used in pediatric sedation and analgesia in the emergency department. Ann Emerg Med. 2004;44:342–377
  5. Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2005;45:177–196
  6. Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med. 2000;342:938–945
  7. Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006;367:766–780
  8. Dailey RH, Stone R, Repert W. Ketamine dissociative anesthesia—emergency department use in children. JACEP. 1979;8:57–58
  9. Pruitt JW, Goldwasser MS, Sabol SR, et al. Intramuscular ketamine, midazolam, and glycopyrrolate for pediatric sedation in the emergency department. J Oral Maxillofac Surg. 1995;53:13–17
  10. Dachs RJ, Innes GM. Intravenous ketamine sedation of pediatric patients in the emergency department. Ann Emerg Med. 1997;29:146–150
  11. Green SM, Rothrock SG, Harris T, et al. Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med. 1998;5:971–976
  12. Kennedy RM, Porter FL, Miller JP, et al. Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics. 1998;102:956–963
  13. Pena BM, Krauss B. Adverse events of procedural sedation and analgesia in a pediatric emergency department. Ann Emerg Med. 1999;34(4 pt 1):483–491
  14. Suskind DL, Park J, Piccirillo JF, et al. Conscious sedation: a new approach for peritonsillar abscess drainage in the pediatric population. Arch Otolaryngol Head Neck Surg. 1999;125:1197–1200
  15. Holloway VJ, Husain HM, Saetta JP, et al. Accident and emergency department led implementation of ketamine sedation in paediatric practice and parental response. J Accid Emerg Med. 2000;17:25–28
  16. Ip U, Saincher A. Safety of pediatric procedural sedation in a Canadian emergency department. CJEM. 2000;2:15–20
  17. McQuillen KK, Steele DW. Capnography during sedation/analgesia in the pediatric emergency department. Pediatr Emerg Care. 2000;16:401–404
  18. Sherwin TS, Green SM, Khan A, et al. Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? (a randomized, double-blind, placebo-controlled trial). Ann Emerg Med. 2000;35:229–238
  19. Acworth JP, Purdie D, Clark RC. Intravenous ketamine plus midazolam is superior to intranasal midazolam for emergency paediatric procedural sedation. Emerg Med J. 2001;18:39–45
  20. Gloor A, Dillier C, Gerber A. Ketamine for short ambulatory procedures in children: an audit. Paediatr Anaesth. 2001;11:533–539
  21. Priestley SJ, Taylor J, McAdam CM, et al. Ketamine sedation for children in the emergency department. Emerg Med (Fremantle). 2001;13:82–90
  22. Hostetler MA, Davis CO. Prospective age-based comparison of behavioral reactions occurring after ketamine sedation in the ED. Am J Emerg Med. 2002;20:463–468
  23. Hostetler MA, Barnard JA. Removal of esophageal foreign bodies in the pediatric ED: is ketamine an option?. Am J Emerg Med. 2002;20:96–98
  24. Luhmann JD, Kennedy RM, McAllister JD, et al. Sedation for peritonsillar abscess drainage in the pediatric emergency department. Pediatr Emerg Care. 2002;18:1–3
  25. Agrawal D, Manzi SF, Gupta R, et al. Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department. Ann Emerg Med. 2003;42:636–646
  26. Godambe SA, Elliot V, Matheny D, et al. Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department. Pediatrics. 2003;112(1 pt 1):116–123
  27. Kim G, Green SM, Denmark TK, et al. Ventilatory response during dissociative sedation in children-a pilot study. Acad Emerg Med. 2003;10:140–145
  28. Pitetti RD, Singh S, Pierce MC. Safe and efficacious use of procedural sedation and analgesia by nonanesthesiologists in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157:1090–1096
  29. Ellis DY, Husain HM, Saetta JP, et al. Procedural sedation in paediatric minor procedures: a prospective audit on ketamine use in the emergency department. Emerg Med J. 2004;21:286–289
  30. Imak A, Oktay C, Cete Y, et al. Acil serviste çocuk hastalarin sedasyonunda kullanilan ketaminin yan etkileri üzerine midazolamin etkisi. Türkiye Acil Tip Dergisi. 2004;4:24–33
  31. McGlone RG, Howes MC, Joshi M. The Lancaster experience of 2.0 to 2.5 mg/kg intramuscular ketamine for paediatric sedation: 501 cases and analysis. Emerg Med J. 2004;21:290–295
  32. Roback MG, Bajaj L, Wathen JE, et al. Preprocedural fasting and adverse events in procedural sedation and analgesia in a pediatric emergency department: are they related?. Ann Emerg Med. 2004;44:454–459
  33. Treston G. Prolonged pre-procedure fasting time is unnecessary when using titrated intravenous ketamine for paediatric procedural sedation. Emerg Med Australas. 2004;16:145–150
  34. Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Am J Emerg Med. 2005;23:142–144
  35. Oktay C, Oktay E, Cete Y, et al. Ketamine is still safe without concurrent midazolam and atropine for pediatric procedures in the emergency department. Pain Clin. 2005;17:255–264
  36. Heinz P, Geelhoed GC, Wee C, et al. Is atropine needed with ketamine sedation? (>a prospective, randomised, double blind study). Emerg Med J. 2006;23:206–209
  37. Kriwanek KL, Wan J, Beaty JH, et al. Axillary block for analgesia during manipulation of forearm fractures in the pediatric emergency department a prospective randomized comparative trial. J Pediatr Orthop. 2006;26:737–740
  38. Losek JD, Reid S. Effects of initial pain treatment on sedation recovery time in pediatric emergency care. Pediatr Emerg Care. 2006;22:100–103
  39. Luhmann JD, Schootman M, Luhmann SJ, et al. A randomized comparison of nitrous oxide plus hematoma block versus ketamine plus midazolam for emergency department forearm fracture reduction in children. Pediatrics. 2006;118:e1078–e1086
  40. Roback MG, Wathen JE, MacKenzie T, et al. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med. 2006;48:605–612
  41. Waterman GD, Leder MS, Cohen DM. Adverse events in pediatric ketamine sedations with or without morphine pretreatment. Pediatr Emerg Care. 2006;22:408–411
  42. Wissler M, Tomaske M, Stutz K, et al. [Intravenous midazolam-ketamine anaesthesia for closed reduction of forearm fractures in children: impact of additional axillary plexus anaesthesia]. Anaesthesist. 2006;55:944–949
  43. Bleiberg AH, Salvaggio CA, Roy LC, et al. Low-dose ketamine: efficacy in pediatric sedation. Pediatr Emerg Care. 2007;23:158–162
  44. Herd DW, Anderson BJ, Keene NA, et al. Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth. 2008;18:36–42
  45. Sacchetti A, Stander E, Ferguson N, et al. Pediatric procedural sedation in the community emergency department: results from the ProSCED registry. Pediatr Emerg Care. 2007;23:218–222
  46. Sharieff GQ, Trocinski DR, Kanegaye JT, et al. Ketamine-propofol combination sedation for fracture reduction in the pediatric emergency department. Pediatr Emerg Care. 2007;23:881–884
  47. Brown L, Christian-Kopp S, Sherwin TS, et al. Adjunctive atropine is unnecessary during ketamine sedation in children. Acad Emerg Med. 2008;15:314–318
  48. McKee MR, Sharieff GQ, Kanegaye JT, et al. Oral analgesia before pediatric ketamine sedation is not associated with an increased risk of emesis and other adverse events. J Emerg Med. 2008;35:23–28
  49. Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesth Analg. 2007;104:509–520
  50. Ikonomidou C, Bittigau P, Koch C, et al. Neurotransmitters and apoptosis in the developing brain. Biochem Pharmacol. 2001;62:401–405
  51. Vutskits L, Gascon E, Tassonyi E, et al. Effect of ketamine on dendritic arbor development and survival of immature GABAergic neurons in vitro. Toxicol Sci. 2006;91:540–549
  52. Wang C, Sadovova N, Fu X, et al. The role of the N-methyl-D-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. Neuroscience. 2005;132:967–977
  53. Hayashi H, Dikkes P, Soriano SG. Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain. Paediatr Anaesth. 2002;12:770–774
  54. Scallet AC, Schmued LC, Slikker W, et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci. 2004;81:364–370
  55. Fredriksson A, Archer T, Alm H, et al. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav Brain Res. 2004;153:367–376
  56. Fredriksson A, Ponten E, Gordh T, et al. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthesiology. 2007;107:427–436
  57. Young C, Jevtovic-Todorovic V, Qin YQ, et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br J Pharmacol. 2005;146:189–197
  58. Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br J Pharmacol. 2000;130:1692–1698
  59. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, et al. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res. 2001;895:264–267
  60. Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging. 2005;26:947–956
  61. Rudin M, Ben-Abraham R, Gazit V, et al. Single-dose ketamine administration induces apoptosis in neonatal mouse brain. J Basic Clin Physiol Pharmacol. 2005;16:231–243
  62. Loepke AW, Soriano SG. An assessment of the effects of general anesthetics on developing brain structure and neurocognitive function. Anesth Analg. 2008;106:1681–1707
  63. Slikker W, Zou X, Hotchkiss CE, et al. Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol Sci. 2007;98:145–158
  64. Olney JW, Young C, Wozniak DF, et al. Do pediatric drugs cause developing neurons to commit suicide?. Trends Pharmacol Sci. 2004;25:135–139
  65. Olney JW, Young C, Wozniak DF, et al. Anesthesia-induced developmental neuroapoptosis (Does it happen in humans?). Anesthesiology. 2004;101:273–275
  66. Todd MM. Anesthetic neurotoxicity: the collision between laboratory neuroscience and clinical medicine. Anesthesiology. 2004;101:272–273
  67. Slikker W, Paule MG, Wright LK, et al. Systems biology approaches for toxicology. J Appl Toxicol. 2007;27:201–217
  68. Zou X, Sadovova N, Patterson TA, et al. The effects of L-carnitine on the combination of, inhalation anesthetic-induced developmental, neuronal apoptosis in the rat frontal cortex. Neuroscience. 2008;151:1053–1065
  69. Anesthetic and Life Support Drugs advisory committee meeting minutes March 27, 2007: neuroapoptosis and the developing human brain. http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4285t1.pdf2008;Accessed October 21, 2008
  70. Majewski-Tiedeken CR, Rabin CR, Siegel SJ. Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug Alcohol Depend. 2008;92:217–227
  71. Wang C, Sadovova N, Hotchkiss C, et al. Blockade of N-methyl-D-aspartate receptors by ketamine produces loss of postnatal day 3 monkey frontal cortical neurons in culture. Toxicol Sci. 2006;91:192–201
  72. Dobbing J, Sands J. Comparative aspects of the brain growth spurt. Early Hum Dev. 1979;3:79–83
  73. Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med. 1998;31:688–697
  74. Roback MG, Bajaj L, Wathen JE, et al. Preprocedural fasting and adverse events in procedural sedation and analgesia in a pediatric emergency department: are they related?. Ann Emerg Med. 2004;44:454–459
  75. Clancy B, Kersh B, Hyde J, et al. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics. 2007;5:79–94
  76. Berde C, Cairns B. Developmental pharmacology across species: promise and problems. Anesth Analg. 2000;91:1–5
  77. Anand KJ, Soriano SG. Anesthetic agents and the immature brain: are these toxic or therapeutic?. Anesthesiology. 2004;101:527–530
  78. Reves IG, Glass PSA, Lubarsky DA, et al. Intravenous nonopioid anesthetics. In:  Miller RD,  Fleisher LA,  Johns RJ editor. Miller's Anesthesia. Philadelphia, PA: Elsevier; 2005;p. 318–361
  79. Idvall J, Ahlgren I, Aronsen KR, et al. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth. 1979;51:1167–1173
  80. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth. 1981;53:805–810
  81. Grant IS, Nimmo WS, McNicol LR, et al. Ketamine disposition in children and adults. Br J Anaesth. 1983;55:1107–1111
  82. Young C, Jevtovic-Todorovic V, Qin YQ, et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br J Pharmacol. 2005;146:189–197
  83. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334:197–202
  84. Hackam DG. Translating animal research into clinical benefit. BMJ. 2007;334:163–164
  85. Allen AL. The diagnosis of acetaminophen toxicosis in a cat. Can Vet J. 2003;44:509–510
  86. Soriano SG, Anand KJ, Rovnaghi CR, et al. Of mice and men: should we extrapolate rodent experimental data to the care of human neonates?. Anesthesiology. 2005;102:866–868
  87. Soriano SG, Anand KJ. Anesthetics and brain toxicity. Curr Opin Anaesthesiol. 2005;18:293–297
  88. Anand KJ, Garg S, Rovnaghi CR, et al. Ketamine reduces the cell death following inflammatory pain in newborn rat brain. Pediatr Res. 2007;62:283–290
  89. Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury?. Anesth Analg. 2005;101:524–534table
  90. Himmelseher S, Pfenninger E, Georgieff M. The effects of ketamine-isomers on neuronal injury and regeneration in rat hippocampal neurons. Anesth Analg. 1996;83:505–512
  91. Engelhard K, Werner C, Eberspacher E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003;96:524–531table
  92. Smith DH, Okiyama K, Gennarelli TA, et al. Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci Lett. 1993;157:211–214
  93. Shapira Y, Lam AM, Artru AA, et al. Ketamine alters calcium and magnesium in brain tissue following experimental head trauma in rats. J Cereb Blood Flow Metab. 1993;13:962–968
  94. Willoughby RE, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. 2005;352:2508–2514
  95. Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg. 1966;45:29–40
  96. Grace RF. The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia. Anaesthesia. 2003;58:904–910
  97. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med. 1990;19:1033–1046
  98. Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7:278–281
  99. Katz L, Wright C, Harter J, et al. Revised label regarding use of succinylcholine in children and adolescents: II. Anesthesiology. 1994;80:243–244
  100. Glaxo Wellcome. I. Anectine (succinylcholine chloride). In: Physician's Desk Reference. Montvale, NJ: Medical Economics Co, Inc; 2000;p. 1151–1153
  101. Badgwell JM, Hall SC, Lockhart C. Revised label regarding use of succinylcholine in children and adolescents: II. Anesthesiology. 1994;80:243
  102. Goudsouzian NG. Recent changes in the package insert for succinylcholine chloride: should this drug be contraindicated for routine use in children and adolescents?. (Summary of the discussions of the anesthetic and life support drug advisory meeting of the Food and Drug Administration, FDA building, Rockville, MD, June 9, 1994) [letter] [see comments] Anesth Analg. 1995;80:207–208
  103. Kent RS. Revised label regarding use of succinylcholine in children and adolescents: II. Anesthesiology. 1994;80:244–245
  104. Lerman J, Berdock SE, Bissonnette B, et al. Succinylcholine warning. Can J Anaesth. 1994;41:165
  105. Morell RC, Berman JM, Royster RI, et al. Revised label regarding use of succinylcholine in children and adolescents. Anesthesiology. 1994;80:242–245
  106. Delphin E, Jackson D, Rothstein P. Use of succinylcholine during elective pediatric anesthesia should be reevaluated. Anesth Analg. 1987;66:1190–1192
  107. Maxwell LG, Yaster M. The myth of conscious sedation. Arch Pediatr Adolesc Med. 1996;150:665–667
  108. Coté CJ, Karl HW, Notterman DA, et al. Adverse sedation events in pediatrics: analysis of medications used for sedation. Pediatrics. 2000;106:633–644
  109. Coté CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributory factors. Pediatrics. 2000;105:805–814
  110. Coté CJ. “Conscious sedation”: time for this oxymoron to go away!. J Pediatr. 2001;139:15–17
  111. Dial S, Silver P, Bock K, et al. Pediatric sedation for procedures titrated to a desired degree of immobility results in unpredictable depth of sedation. Pediatr Emerg Care. 2001;17:414–420
  112. Yon JH, Niel-Johnson J, Carter LB, et al. Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. Neuroscience. 2005;135:815–827
  113. Miner JR, Burton JH. Clinical practice advisory: emergency department procedural sedation with propofol. Ann Emerg Med. 2007;50:182–187
  114. Green SM. Propofol in emergency medicine: further evidence of safety. Emerg Med Australas. 2007;19:389–393
  115. Green SM, Krauss B. Barriers to propofol use in emergency medicine. Ann Emerg Med. 2008;52:392–398
  116. Cattano D, Young C, Straiko MM, et al. Subanesthetic doses of propofol induce neuroapoptosis in the infant mouse brain. Anesth Analg. 2008;106:1712–1714
  117. Wang QJ, Li KZ, Yao SL, et al. Different effects of isoflurane and sevoflurane on cytotoxicity. Chin Med J (Engl). 2008;121:341–346
  118. Yang H, Liang G, Hawkins BJ, et al. Inhalational anesthetics induce cell damage by disruption of intracellular calcium homeostasis with different potencies. Anesthesiology. 2008;109:243–250
  119. Korfias S, Stranjalis G, Papadimitriou A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem. 2006;13:3719–3731
  120. Lamers KJ, Vos P, Verbeek MM, et al. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull. 2003;61:261–264
  121. van Engelen BG, Lamers KJ, Gabreels FJ, et al. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 1992;38:813–816

 Supervising editors: Michael W. Shannon, MD; Donald M. Yealy, MD

 Dr. Shannon and Dr. Yealy were the supervising editors on this article. Dr. Green did not participate in the editorial review or decision to publish this article.

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.

 Publication date: Available online November 6, 2008.

 Reprints not available from the authors.

PII: S0196-0644(08)01855-6

doi: 10.1016/j.annemergmed.2008.10.003

Annals of Emergency Medicine
Volume 54, Issue 2 , Pages 181-190 , August 2009

Article Tools

* Image Usage & Resolution